{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:22:52Z","timestamp":1791476572035,"version":"4.3.4"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Acta Biochim. Pol."],"abstract":"<jats:p>Urinary tract infections (UTIs) are among the most common bacterial infections worldwide and increasing antimicrobial resistance (AMR) challenges conventional antibiotic treatments. Phage therapy (PT) has emerged as a promising alternative due to its specificity, safety and efficacy against multidrug-resistant (MDR) pathogens causing infectious diseases. PT demonstrates significant potential in treating chronic and recurrent UTIs, also including catheter-associated infection by reducing bacterial biofilms, delaying catheter blockage, and enhancing antibiotic efficacy when used in combination. Clinical trials and case studies have reported high rates of bacterial eradication and symptom improvement with minimal side effects. Although endotoxin release and immune activation during treatment should continue to be investigated. The aim of this review is to present issues related to the use of phages in the treatment of UTIs of various etiological origins in selected patients, including those with comorbidities, taking into account the legal regulations, safety and effectiveness of this experimental therapy. The growing prevalence of MDR uropathogens highlights the urgent need for alternative therapies, such as those based on phages in order to treat antibiotic-resistant infections and improve patient outcomes. Despite the great potential of PT, its clinical implementation and use of phages as a routine treatment for bacterial infections requires rigorous trials, standardized production protocols and regulatory advancements.<\/jats:p>","DOI":"10.3389\/abp.2025.14264","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T23:13:01Z","timestamp":1739229181000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Phages as potential life-saving therapeutic option in the treatment of multidrug-resistant urinary tract infections"],"prefix":"10.3389","volume":"72","author":[{"given":"Beata","family":"Zalewska-Pi\u0105tek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalina","family":"Nag\u00f3rka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1089\/phage.2023.0024","article-title":"Phage therapy in the management of urinary tract infections: a comprehensive systematic review","volume":"4","author":"Al-Anany","year":"2023","journal-title":"Phage (New Rochelle)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jama.2019.21377","article-title":"Recurrent urinary tract infections in adult women","volume":"323","author":"Aslam","year":"2020","journal-title":"JAMA"},{"key":"B3","volume-title":"Acute pyelonephritis. StatPearls","author":"Belyayeva","year":"2024"},{"key":"B4","article-title":"Urinary tract infection","volume-title":"Catheter-associated urinary tract infection basics","year":"2024"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-394438-2.00001-3","article-title":"Phage therapy-history from Twort and d\u2019Herelle through soviet experience to current approaches","volume":"83","author":"Chanishvili","year":"2012","journal-title":"Adv. Virus Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12941-021-00433-y","article-title":"Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review","volume":"20","author":"Chegini","year":"2021","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"B7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.idc.2013.09.002","article-title":"Diagnosis, management, and prevention of catheter-associated urinary tract infections","volume":"28","author":"Chenoweth","year":"2014","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/ph16101347","article-title":"The safety of bacteriophages in treatment of diseases caused by multidrug-resistant bacteria","volume":"16","author":"Chung","year":"2023","journal-title":"Pharm. (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1093\/cid\/ciz782","article-title":"Eradication of a multidrug-resistant, carbapenemase-producing Klebsiella pneumoniae isolate following oral and intra-rectal therapy with a custom made, lytic bacteriophage preparation","volume":"70","author":"Corbellino","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B10","first-page":"373","article-title":"Sur un microbe invisible antagoniste des bacilles dysen-te\u2019riques","volume":"165","author":"D\u2019Herelle","year":"1917","journal-title":"Comptes Rendus Acad\u00e9mie Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.resmic.2007.07.005","article-title":"On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D\u2019Herelle, presented by Mr. Roux. 1917","volume":"158","author":"D\u2019Herelle","year":"2007","journal-title":"Res. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/1751-7915.14268","article-title":"Novel antimicrobial strategies to treat multi\u2010drug resistant Staphylococcus aureus infections","volume":"16","author":"Douglas","year":"2023","journal-title":"Microb. Biotechnol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1093\/jac\/dky263","article-title":"Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected cocktail of bacteriophages","volume":"73","author":"Ferry","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B14","first-page":"780","article-title":"On antibacterial action of culture of penicillium, with special reference to their use in isolation of B. influenzae. 1929","volume":"79","author":"Fleming","year":"2001","journal-title":"Bull. World Health Organ."},{"key":"B15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores\u2010Mireles","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","article-title":"Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"B17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ijantimicag.2017.08.013","article-title":"Phages in urban wastewater have the potential to disseminate antibiotic resistance","volume":"50","author":"Gunathilaka","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/antibiotics10020202","article-title":"Genetic and chemical engineering of phages for controlling multidrug-resistant bacteria","volume":"10","author":"Guo","year":"2021","journal-title":"Antibiotics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMcp1104429","article-title":"Uncomplicated urinary tract infection","volume":"366","author":"Hooton","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1128\/CMR.00019-07","article-title":"Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis","volume":"21","author":"Jacobsen","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1056\/nejmcp1702758","article-title":"Acute pyelonephritis in adults","volume":"378","author":"Johnson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"692614","DOI":"10.3389\/fphar.2021.692614","article-title":"Case report: chronic bacterial prostatitis treated with phage therapy after multiple failed antibiotic treatments","volume":"12","author":"Johri","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.33073\/pjm-2019-048","article-title":"Antibiotic resistance among uropathogenic Escherichia coli","volume":"68","author":"Kot","year":"2019","journal-title":"Pol. J. Microbiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","article-title":"European association of urology guidelines on urological infections: summary of the 2024 guidelines","volume":"86","author":"Kranz","year":"2024","journal-title":"Eur. Urol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"ofy064","DOI":"10.1093\/ofid\/ofy064","article-title":"Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection","volume":"5","author":"LaVergne","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.euf.2024.07.006","article-title":"Innovations in phage therapy for urinary tract infection","volume":"10","author":"Leitner","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"B27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S1473-3099(20)30330-3","article-title":"Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial","volume":"21","author":"Leitner","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11908\u2010013\u20100315\u20107","article-title":"Treatment of complicated urinary tract infections with an emphasis on drug\u2010resistant gram\u2010negative uropathogens","volume":"15","author":"Levison","year":"2013","journal-title":"Curr. Infect. Dis. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"026","DOI":"10.29328\/journal.ijcv.1001059","article-title":"Resolution of chronic bacterial prostatitis with bacteriophage-antibiotic therapy","volume":"8","author":"Lia","year":"2024","journal-title":"Int. J. Clin. Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","article-title":"Phage therapy: an alternative to antibiotics in the age of multi-drug resistance","volume":"8","author":"Lin","year":"2017","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cmi.2020.04.039","article-title":"Pharmacokinetics\/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a proof-of-concept study","volume":"26","author":"Lin","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1016\/j.apsb.2022.05.007","article-title":"Recent advances in bacteriophage-based therapeutics: insight into the post-antibiotic era","volume":"12","author":"Ling","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"B33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature14098","article-title":"A new antibiotic kills pathogens without detectable resistance","volume":"517","author":"Ling","year":"2015","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/v13071268","article-title":"The safety and toxicity of phage therapy: a review of animal and clinical studies","volume":"13","author":"Liu","year":"2021","journal-title":"Viruses"},{"key":"B70","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1086\/675718","article-title":"Strategies to prevent catheter\u2010associated urinary tract infections in acute care hospitals: 2014 updates","volume":"35","author":"Lo","year":"2014","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.clinthera.2020.07.014","article-title":"Phage therapy in the resistance era: Where do we stand and where are we going?","volume":"42","author":"Luong","year":"2020","journal-title":"Clin. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12223\u2010019\u201000750\u2010y","article-title":"Managing urinary tract infections through phage therapy: a novel approach","volume":"65","author":"Malik","year":"2019","journal-title":"Folia Microbiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/nau.21003","article-title":"Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database","volume":"30","author":"Manack","year":"2011","journal-title":"Neurourol. Urodynamics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.22092\/ari.2021.356004.1762","article-title":"A novel phage cocktail therapy of the urinary tract infection in a mouse model","volume":"76","author":"Mijbel Ali","year":"2021","journal-title":"Arch. Razi. Inst."},{"key":"B39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bios.2016.02.059","article-title":"An in-situ infection detection sensor coating for urinary catheters","volume":"81","author":"Milo","year":"2016","journal-title":"Biosens. Bioelectron."},{"key":"B40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.22207\/JPAM.18.1.49","article-title":"How phage therapy works, its advantages and disadvantages: Mini review","volume":"18","author":"Mishra","year":"2024","journal-title":"J. Pure Appl. Microbiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.cmi.2023.01.021","article-title":"Pharmacokinetics\/pharmacodynamics of phage therapy: A major hurdle to clinical translation","volume":"29","author":"Nang","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"B43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4172\/1747-0862.1000050","article-title":"The role of regulated clinical trials in the development of bacteriophage therapeutics","volume":"6","author":"Parracho","year":"2012","journal-title":"J. Mol. Genet. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3389\/fphar.2019.00513","article-title":"Advantages and limitations of bacteriophages for the treatment of bacterial infections","volume":"10","author":"Principi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11262-020-01735-7","article-title":"Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections","volume":"56","author":"Reuter","year":"2020","journal-title":"Virus Genes"},{"key":"B46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.12968\/jowc.2009.18.6.42801","article-title":"Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial","volume":"18","author":"Rhoads","year":"2009","journal-title":"J. Wound Care"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e13391","DOI":"10.1111\/tid.13391","article-title":"Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy","volume":"23","author":"Rostkowska","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"veae028","DOI":"10.1093\/ve\/veae028","article-title":"Lytic\/lysogenic transition as a life-history switch","volume":"10","author":"Roughgarden","year":"2024","journal-title":"Virus Evol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"796132","DOI":"10.3389\/fmicb.2022.796132","article-title":"Development of phage cocktails to treat E. coli catheter-associated urinary tract infection and associated biofilms","volume":"13","author":"Sanchez","year":"2022","journal-title":"Front. Microbiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3390\/molecules28041762","article-title":"A comprehensive overview of the antibiotics approved in the last two decades: retrospects and prospects","volume":"28","author":"Shi","year":"2023","journal-title":"Molecules"},{"key":"B51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2022.11.017","article-title":"Phage therapy: from biological mechanisms to future directions","volume":"186","author":"Strathdee","year":"2023","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e241668","DOI":"10.1148\/radiol.241668","article-title":"Comparing large language model and human reader accuracy with New England Journal of Medicine image challenge case image inputs","volume":"313","author":"Suh","year":"2024","journal-title":"Radiology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","article-title":"Bacteriophage therapy","volume":"45","author":"Sulakvelidze","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/jac\/dky043","article-title":"Applying definitions for multidrug resistance, extensive drug resistance and pandrug resistance to clinically significant livestock and companion animal bacterial pathogens","volume":"73","author":"Sweeney","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/IDR.S234353","article-title":"How phages overcome the challenges of drug resistant bacteria in clinical infections","volume":"13","author":"Taati Moghadam","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/v13102049","article-title":"Phage therapy related microbial succession associated with successful clinical outcome for a recurrent urinary tract infection","volume":"13","author":"Terwilliger","year":"2021","journal-title":"Viruses"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/s0140-6736(01)20383-3","article-title":"An investigation on the nature of ultra-microscopic viruses","volume":"186","author":"Twort","year":"1915","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3389\/fmicb.2018.01832","article-title":"Adapted bacteriophages for treating urinary tract infections","volume":"9","author":"Ujmajuridze","year":"2018","journal-title":"Front. Microbiol."},{"key":"B59","article-title":"At UN, global leaders commit to act on antimicrobial resistance: collective effort to address a challenge to health, food security, and development. Press release: high-Level meeting on Antimicrobial Resistance","volume-title":"General assembly of the united Nations","year":"2016"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","article-title":"Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review","volume":"22","author":"Uyttebroek","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.virusres.2017.07.015","article-title":"Effects of single and combined use of bacteriophages and antibiotics to inactivate Escherichia coli","volume":"240","author":"Val\u00e9rio","year":"2017","journal-title":"Virus Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1038\/s41598-017-08336-9","article-title":"Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages","volume":"7","author":"Van Belleghem","year":"2017","journal-title":"Sci. Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/fcimb.2020.00414","article-title":"Proteus mirabilis biofilm: development and therapeutic strategies","volume":"10","author":"Wasfi","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/RRU.S273663","article-title":"Catheter-associated urinary tract infections: current challenges and future prospects","volume":"14","author":"Werneburg","year":"2022","journal-title":"Res. Rep. Urology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"996778","DOI":"10.3389\/fcimb.2022.996778","article-title":"Bacterial DNA involvement in carcinogenesis","volume":"12","author":"Yangyanqiu","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"114","DOI":"10.18565\/urology.2024.1.114-118","article-title":"Experience with the use of bacteriophages in patients with neurogenic lower urinary tract dysfunction, complicated by recurrent lower urinary tract infection","author":"Zaitsev","year":"2024","journal-title":"Urologiia"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/ph16121638","article-title":"Phage therapy\u2014challenges, opportunities and future prospects","volume":"16","author":"Zalewska-Pi\u0105tek","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B68","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/antibiotics9060304","article-title":"Phage therapy as a novel strategy in the treatment of urinary tract infections caused by E. coli","volume":"9","author":"Zalewska-Pi\u0105tek","year":"2020","journal-title":"Antibiotics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5604\/01.3001.0013.2022","article-title":"Pathomechanism of urinary tract infections caused by uropathogenic E. coli strains","volume":"73","author":"Zalewska\u2010Pi\u0105tek","year":"2019","journal-title":"Post\u0119py Hig. i Med. Do\u015bwiadczalnej"}],"container-title":["Acta Biochimica Polonica"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/abp.2025.14264\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T23:13:06Z","timestamp":1739229186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/abp.2025.14264\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":70,"alternative-id":["10.3389\/abp.2025.14264"],"URL":"https:\/\/doi.org\/10.3389\/abp.2025.14264","relation":{},"ISSN":["1734-154X"],"issn-type":[{"value":"1734-154X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"article-number":"14264"}}